Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
Maurizio Averna, Luc Missault, Margus Viigimaa, Philippe Brudi, Arvind Shah, William Taggart, Qian Dong, Margus Viigimaa, Margus Viigimaa, Amy O. Johnson-Levonas, Helena Vaverkova, Michel Farnier
Fingerprint
Entra nei temi di ricerca di 'Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome'. Insieme formano una fingerprint unica.